

## APPENDIX 21

### SPECIAL CONDITIONS FOR REGISTRATION OF A PARTICULAR PRODUCT OR GROUP OF PRODUCTS

---

| NO. | PRODUCTS  |
|-----|---|
| 1.  | <b><u>BLOOD PRODUCTS</u></b>  |
| 2.  | <b><u>HUMAN GROWTH HORMONE</u></b> (Somatotropin, Somatropin)               |
| 3.  | <b><u>KETOCONAZOLE</u></b>  |
| 4.  | <b><u>MAGNOLIA OFFICINALIS</u></b>  |
| 5.  | <b><u>MIDAZOLAM</u></b>   |
| 6.  | <b><u>PARACETAMOL IN COMBINATION WITH CAFFEINE</u></b>                      |
| 7.  | <b><u>PARACETAMOL INTRAVENOUS INJECTION</u></b>                             |
| 8.  | <b><u>RETINOIDS INDICATED FOR THE TREATMENT OF SKIN DISEASES (ORAL)</u></b> |
| 9.  | <b><u>VACCINES</u></b>  |
| 10. | <b><u>COVID-19 VACCINES</u></b>   |

---

| NO. | SPECIAL CONDITIONS/ REQUIREMENTS   |
|-----|--|
| 1.  | <p><b>BLOOD PRODUCTS</b></p> <p>a) Each batch of product must comply with WHO requirements for the product.</p> <p>b) The following documents must be enclosed with each bath of the product imported into Malaysia:</p> <ul style="list-style-type: none"> <li>i. Batch Release Certificate from the relevant authority in the country of manufacture</li> <li>ii. Certificate confirming that the blood or plasma used in the production of the lot is tested and found to be negative for HIV antibody, HbsAg, and HCV, and that high-risk donors were excluded.</li> <li>iii. Certificate of analysis.</li> </ul>  |
| 2.  | <p><b>HUMAN GROWTH HORMONE</b> (Somatotropin, Somatropin)</p> <p>A proper record of product supplied stating the product name, product registration number, name, address and contact number of purchaser (prescriber) shall be kept and submitted to the Authority upon request.</p>  |
| 3.  | <p><b>KETOCONAZOLE</b></p> <p>Oral products containing ketoconazole are restricted for hospital use only.</p>  |
| 4.  | <p><b>MAGNOLIA OFFICINALIS</b></p> <p>a) <i>Magnolia officinalis</i> is <b>only allowed</b> for products that comply with Chinese Traditional medicine formulation based on recognized references such as <i>Pharmacopeia of the People's Republic of China, Taiwan Herbal Pharmacopeia, etc.</i></p> <p>b) Product Registration Holder shall ensure that the product is sold or supplied to Registered Traditional Chinese Medicine Practitioners only.</p> <p>c) Manufacturers or Importers and Wholesalers shall ensure that the product is manufactured or imported and sold wholesale or supplied to Registered Traditional Chinese Medicine Practitioners only.</p> <p>Reference: <a href="#">NPRA.600-1/9/12 (11)</a> Pekeliling Berkenaan Pengemaskinian Status Bahan Aktif <i>Magnolia Officinalis</i> Dalam Drug Registration Guidance Document (DRGD)</p> |
| 5.  | <p><b>MIDAZOLAM</b></p> <p>Products containing midazolam are restricted for use in government and private hospitals and specialist clinics only.</p>   |

| NO. | SPECIAL CONDITIONS/ REQUIREMENTS  |
|-----|---|
| 6.  | <p><b>PARACETAMOL IN COMBINATION WITH CAFFEINE</b></p> <p>a) For products containing a combination of paracetamol and caffeine:<br/>Dose unit of caffeine for adults is 65mg and maximum dose of caffeine is 520mg per day<br/>Dose unit for paracetamol is 500mg with the maximum dose of 4,000mg per day or 8 tablets daily.</p> <p>b) Products containing caffeine for pediatric patients are not allowed.</p> <p>c) Allowable packing size should not exceed 20 tablets/ capsules.</p>  |
| 7.  | <p><b>PARACETAMOL INTRAVENOUS INJECTION</b></p> <p>Products containing paracetamol in the form of intravenous injection are restricted for hospital use only.</p>   |
| 8.  | <p><b>RETINOIDS INDICATED FOR THE TREATMENT OF SKIN DISEASES (ORAL)</b></p> <p>a) The product registration holder shall ensure that the product shall only be sold or supplied to, and prescribed by:</p> <ol style="list-style-type: none"> <li>i. Dermatologists registered in the National Specialist Register; or</li> <li>ii. Dermatologists serving in any government health facilities.</li> </ol> <p>b) The product registration holder shall submit a proper record containing the following information to the Authority upon request.</p> <ol style="list-style-type: none"> <li>i. Name of product;</li> <li>ii. Product registration number;</li> <li>iii. Date &amp; quantity of product manufactured/ imported and supplied; and</li> <li>iv. Name, address &amp; contact number of purchaser (prescriber).</li> </ol> <p>c) The prescriber shall keep and maintain proper patient records for audit purpose, if any.</p> <p><b>Reference:</b> Directive No. 17, 2020. <a href="#">NPRA.600-1/9/13 (8)</a> Direktif Berkenaan Pindaan Syarat Pendaftaran Khas Bagi Produk Yang Mengandungi Oral Retinoid Yang Diindikasikan Untuk Rawatan Penyakit Kulit (14 September 2020)</p> |
| 9.  | <p><b>VACCINES</b></p> <p>a) Each batch of the product must comply with WHO requirements for the product.</p> <p>b) A batch release certificate must be enclosed with each batch of the product imported into Malaysia.</p>   |

| NO. | SPECIAL CONDITIONS/ REQUIREMENTS   |
|-----|--|
| 10. | <p data-bbox="277 253 552 286"><b>COVID-19 VACCINES</b></p> <p data-bbox="325 322 1401 398">a) The product registration holder shall ensure that the product shall only be sold or supplied to the government or other party authorized by the government only.</p> <p data-bbox="277 445 424 479"><b>Reference:</b></p> <p data-bbox="277 510 1453 645"><i>Keputusan Pihak Berkuasa Kawalan Dadah (PBKD) Berkenaan Penetapan Syarat Pendaftaran Bagi Vaksin COVID-19 Yang Diluluskan Pendaftaran Bersyarat Hanya Boleh Dijual Dan Dibekal Kepada Pihak Kerajaan Atau Pihak Yang Dibenarkan Oleh Kerajaan, <a href="#">NPRA.600-1/9/7 (43)</a> (10 March 2021)</i></p> |